Blood Biomarker Signature in Glioma
Are Gliomas in Adults Associated With a Unique Identifying Blood Biomarker Signature?
Sponsor: Cancer Trials Ireland
Terminated
As per the HRBs new funding model, HRBs investment will not support costs associated with routine patient care or translational studies, biobanks, patient registries and questionnaires. Therefore, a decision was made to cease further study follow up.
Other terminated trials from Cancer Trials Ireland
Other Glioma of Brain trials with similar outcome
Listed as NCT03698201, this observational or N/A phase trial focuses on Glioma of Brain and remains terminated or withdrawn. Sponsored by Cancer Trials Ireland, it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Aug 2025 — Present [monthly]
Terminated
-
Sep 2024 — Aug 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
May 2023 — Jul 2024 [monthly]
Terminated
-
Feb 2022 — May 2023 [monthly]
Terminated
Status: Recruiting → Terminated
▶ Show 4 earlier versions
-
Jan 2021 — Feb 2022 [monthly]
Recruiting
-
Mar 2020 — Jan 2021 [monthly]
Recruiting
-
Feb 2019 — Mar 2020 [monthly]
Recruiting
-
Nov 2018 — Feb 2019 [monthly]
Recruiting
First recorded
Jul 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Trials Ireland
- Royal College of Surgeons, Ireland
For direct contact, visit the study record on ClinicalTrials.gov .